DelveInsight’s ‘Biliary Tract Cancer (BTC)– Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of biliary tract cancer (BTC) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The biliary tract cancer market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted biliary tract cancer market Size from 2017 to 2030, segmented by seven major markets. The report also covers the current biliary tract cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
Biliary Tract Cancer Overview
Biliary Tract Cancer constitutes epithelial malignancies of the biliary tree and includes the following: gallbladder cancer (GBC), intrahepatic CCA (iCCA) and extrahepatic CCA (eCCA).The extrahepatic disease may be split into perihilar (Klatskin’s tumor) and distal CCA. BTC constitutes approximately 3% of all gastrointestinal malignancies and is the most common hepatobiliary cancer after hepatocellular carcinoma. Primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), cirrhosis due to other causes, hepatitis C and congenital malformations such as choledochal cysts and multiple biliary papillomatosis are also associated with an increased risk of developing BTC. In addition, patients with germline mutations resulting in Lynch syndrome and BRCA1 and BRCA2 (breast cancer gene 1 and 2) genetic aberrations are also predisposed to BTC.
Gallbladder cancer originates in the cells of the gallbladder, and most are adenocarcinomas, which begin in the gland cells of the gallbladder lining. While, CCA is an epithelial malignancy originating from transformed cholangiocytes, with preclinical studies suggesting hepatic progenitor cells as the origin. iCCA can emerge at any point in the intrahepatic biliary tree, ranging from main bile ducts to the segmental bile ducts. In contrast to HCC, iCCA usually develops in non-cirrhotic liver. pCCA can arise in the right and/or left hepatic duct and/or at their junction (so-called perihilar bile ducts), and dCCA involves the common bile duct. The current term extrahepatic Cholangiocarcinoma (eCCA) is now discouraged from using as it combines subtypes with distinct clinicopathological features, origins, prognosis, and therapeutic options. Ampullary cancer originates in the area where the common bile duct meets the pancreatic duct, which is called the Ampulla of Vater.
Inflammation and cholestasis are key factors in cholangiocarcinogenesis. Next-generation sequencing has identified somatic mutations in oncogenes (i.e., KRAS), tumor suppressor (i.e., TP53 and SMAD4), and chromatin-modifying genes (i.e., ARID1A, BAP1, and PBMR1) in CCA. Furthermore, the tumor commonly metastasizes via lymphatic spread to the regional lymph nodes, followed by hematogenous metastasis to the liver, lungs, and peritoneum. The majority of cholangiocarcinomas are adenocarcinomas with variable grades of differentiation (mainly well-differentiated adenocarcinomas), although several uncommon types are also encountered, such as adenosquamous, squamous, mucinous, and anaplastic carcinomas. Jaundice and abdominal pain are the most common presentations of BTC.
A diagnosis of biliary tract cancer is usually based on the results of clinical examination of the abdomen, imaging scans using ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT), and a biopsy. Further investigations can help to determine how advanced the cancer is (the ‘stage’). For example, MRI of the biliary tract, a CT scan of the chest and an ultrasound scan of the lymph nodes are commonly used to see how far cancer has spread. Biliary tract cancer is staged according to tumor size, whether it has spread to the lymph nodes and whether it has spread into the liver, lungs or other parts of the body. This information is used to help decide the best treatment.
Treatment options for the early-stage disease include surgery followed by adjuvant chemotherapy. For patients with locally advanced disease, locoregional therapies (e.g., trans-arterial chemoembolization (TACE)) and external beam radiation therapy (EBRT) may be considered. However, these have not yet been validated in prospective randomized controlled trials, and therefore, their use is very variable. For patients with locally advanced and metastatic disease, the combination of gemcitabine and cisplatin has been shown to improve survival.
Biliary Tract Cancer Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the biliary tract cancer market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the
United States, Europe, and Japan.
The DelveInsight Biliary Tract Cancer market report gives a thorough understanding of biliary tract cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for biliary tract cancer in the US, Europe, and Japan.
Biliary Tract Cancer Epidemiology
The Biliary Tract Cancer epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical and forecasted Biliary Tract Cancer epidemiology segmented as the total incident cases of biliary tract cancer, age-specific cases of biliary tract cancer, stage-specific cases of biliary tract cancer and mutation specific cases of biliary tract cancer. The report includes the incident scenario of Biliary Tract Cancer symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country-wise Biliary Tract Cancer Epidemiology
The epidemiology segment also provides the Biliary Tract Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total incident population of biliary tract cancer in the 7MM countries was estimated to be 70,111 cases in 2017.
The drug chapter segment of the Biliary tract cancer report encloses the detailed analysis of biliary tract cancer marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II and Phase-I/II) pipeline drugs. It also helps to understand the biliary tract cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late-stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy. Few more aggressive surgical approaches and improved radiologic techniques have resulted in improved R0 (tumor-free margins) resection rates, but recurrence rates remain high.
Products detail in the report…
Ivosidenib (AG-120) (Agios Pharmaceuticals) is a first-in-class, oral, potent, reversible, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. Agios Pharmaceuticals is developing Ivosidenib for the treatment of patients with cancers that harbor an IDH1 mutation. The company evaluated the product in late-stage clinical studies for cholangiocarcinoma with an IDH1 Mutation and presented the positive results of the phase III trial.
The company plans to submit a supplemental new drug application for Tibsovo in previously treated IDH1-mutant cholangiocarcinoma in the first quarter of 2021. Ivosidenib is marketed and commercialized under the brand name Tibsovo for Acute myeloid leukemia.
Infigratinib (BGJ398) (QED Therapeutics) is an investigational, orally administered FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven diseases, including cholangiocarcinoma (bile duct cancer) and others. It sparingly inhibits FGFR4; patients may tolerate it better than pan–FGFR1-4 inhibitors.
QED Therapeutics is developing Infigratinib in the phase III PROOF trial, in first Line Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations and phase II in second-line cholangiocarcinoma (bile duct cancer). QED intends to submit an NDA with the US FDA for second and later-line cholangiocarcinoma in 2020. The FDA awarded infigratinib a Fast Track Designation for adults with first-line advanced or metastatic cholangiocarcinoma and an orphan drug designation for cholangiocarcinoma.
Products detail in the report…
Biliary Tract Cancer Market Outlook
The Biliary Tract Cancer market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Biliary Tract Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of biliary tract cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, biliary tract cancer market in the 7MM is expected to change in the study period 2017–2030.
The BTC market consists of various unmet needs, which include lack of treatment, poor understanding of molecular components involved in signaling pathways, and lack of awareness. Various research studies have focused on developing treatments for CCA to counter the current unmet needs of the market and provide better treatment options for CCA. With the continuous efforts in research and development, few companies are developing therapies
This section includes a glimpse of the biliary tract cancer market in the 7MM. The market size of biliary tract cancer in the seven major markets was found to be USD 904 Million in 2017.
The United States: Market Outlook
This section provides the total biliary tract cancer market size and market size by therapies of biliary tract cancer in the United States.
The United States accounts for the highest market size of biliary tract cancer in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Hitherto, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late-stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy. Few more aggressive surgical approaches and improved radiologic techniques have resulted in improved R0 (tumor-free margins) resection rates, but recurrence rates remain high.
As a part of palliative treatment, systemic chemotherapy is the treatment of choice for patients with locally advanced or inoperable disease Cisplatin/gemcitabine is the reference chemotherapy regimen.event.
Recently, with so much of efforts going into this area, Pemigatinib (Pemazyre) by Incyte Corporation was approved in the US and EU for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.
EU-5 Countries: Market Outlook
The total biliary tract cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.
Japan Market Outlook
The total biliary tract cancer market size and market size by therapies of biliary tract cancer in Japan are also mentioned.
Biliary Tract Cancer Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers biliary tract cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Biliary Tract Cancer Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II and Phase I/II stage. It also analyses biliary tract cancer key players involved in developing targeted therapeutics.
Major players include QED Therapeutics, Delcath Systems, Taiho Oncology, Merck Sharp & Dohme, Agios Pharmaceuticals, whose key products are expected to get launched in the US market by 20XX.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for biliary tract cancer emerging therapies.
To keep up with current market trends, we take KOLs and SME’s opinion working in Biliary Tract Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Biliary Tract Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Biliary Tract Cancer market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Biliary Tract Cancer Report Insights
Biliary Tract Cancer Report Key Strengths
Biliary Tract Cancer Report Assessment
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Executive Summary of Biliary Tract Cancers (BTCs)
3. Competitive Intelligence Analysis for Biliary Tract Cancers (BTCs)
4. Biliary Tract Cancers (BTCs): Market Overview at a Glance
4.1. Biliary Tract Cancers (BTCs) Total Market Share (%) Distribution in 2017
4.2. Biliary Tract Cancers (BTCs) Total Market Share (%) Distribution in 2030
5. Biliary Tract Cancers (BTCs): Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Biliary Tract Cancers (BTCs) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Biliary Tract Cancers (BTCs) Treatment and Management
8.2. Biliary Tract Cancers (BTCs) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Biliary Tract Cancers (BTCs) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Biliary Tract Cancers (BTCs): Seven Major Market Analysis
13.1. Key Findings
13.2. Biliary Tract Cancers (BTCs) Market Size in 7MM
13.3. Biliary Tract Cancers (BTCs) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Biliary Tract Cancers (BTCs) Total Market Size in the United States
15.1.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Biliary Tract Cancers (BTCs) Total Market Size in Germany
15.3.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Biliary Tract Cancers (BTCs) Total Market Size in France
15.4.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Biliary Tract Cancers (BTCs) Total Market Size in Italy
15.5.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Biliary Tract Cancers (BTCs) Total Market Size in Spain
15.6.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Biliary Tract Cancers (BTCs) Total Market Size in the United Kingdom
15.7.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Biliary Tract Cancers (BTCs) Total Market Size in Japan
15.8.3. Biliary Tract Cancers (BTCs) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Biliary Tract Cancers (BTCs)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
List of Table
Table 1: TNM and AJCC/ UICC Staging Systems for iCCA
Table 2: AJCC staging of iCCA: Comparison of 7th and 8th editions
Table 3: TNM and AJCC/UICC Staging Systems for Perihilar and Distal CCA
Table 4: TNM and AJCC/UICC Staging Systems for Gall Bladder Cancer
Table 5: Risk Factors for BTC
Table 6: Host genetic polymorphism associated with cholangiocarcinoma
Table 7: Recommendations of ICCA for Diagnosis
Table 8: ESMO Clinical Practice Guidelines for treatment and follow-up
Table 9: Total Incident Cases of Biliary tract cancers in the 7MM (2017–2030)
Table 10: Total Incident Cases of BTC in the US (2017–2030)
Table 11: Age-specific Cases of BTC in the US (2017–2030)
Table 12: Mutation-specific Cases of BTC in the US (2017–2030)
Table 13: Stage-specific Cases of BTC in the US (2017–2030)
Table 14: Total Incident Cases of BTC in Germany (2017–2030)
Table 15: Age-specific Cases of BTC in Germany (2017–2030)
Table 16: Mutation-specific Cases of BTC in Germany (2017–2030)
Table 17: Stage-specific Cases of BTC in Germany (2017–2030)
Table 18: Total Incident Cases of BTC in France (2017–2030)
Table 19: Age-specific Cases of BTC in France (2017–2030)
Table 20: Mutation-specific Cases of BTC in France (2017–2030)
Table 21: Stage-specific Cases of BTC in France (2017–2030)
Table 22: Total Incident Cases of BTC in Italy (2017–2030)
Table 23: Age-specific Cases of BTC in Italy (2017–2030)
Table 24: Mutation-specific Cases of BTC in Italy (2017–2030)
Table 25: Stage-specific Cases of BTC in Italy (2017–2030)
Table 26: Total Incident Cases of BTC in Spain (2017–2030)
Table 27: Age-specific Cases of BTC in Spain (2017–2030)
Table 28: Mutation-specific Cases of BTC in Spain (2017–2030)
Table 29: Stage-specific Cases of BTC in Spain (2017–2030)
Table 30: Total Incident Cases of BTC in UK (2017–2030)
Table 31: Age-specific Cases of BTC in UK (2017–2030)
Table 32: Mutation-specific Cases of BTC in UK (2017–2030)
Table 33: Stage-specific Cases of BTC in UK (2017–2030)
Table 34: Total Incident Cases of BTC in Japan (2017–2030)
Table 35: Age-specific Cases of BTC in Japan (2017–2030)
Table 36: Mutation-specific Cases of BTC in Japan (2017–2030)
Table 37: Stage-specific Cases of BTC in Japan (2017–2030)
Table 38: Recommendations of the British Society of Gastroenterology guidelines
Table 39: Recommendations of iCCA for management
Table 40: Levels of evidence and grades of recommendation
Table 41: ESMO Clinical Practice Guidelines for treatment and follow-up
Table 42: ESMO Clinical Practice Guidelines for treatment and follow-up
Table 43: NCCN Guidelines for Hepatobiliary Cancer 2020
Table:44 NCCN Guidelines for Principles of Systemic Therapy**
Table 45:: INCB054828, Clinical Trial Description, 2020
Table 46: Larotrectinib, Clinical Trial Description, 2020
Table 47: Entrectinib, Clinical Trial Description, 2020
Table 48: Key Cross: Emerging Therapies (III& II/III)
Table 49: Key Cross: Emerging Therapies (II& I/II)
Table 50: AG-120, Clinical Trial Description, 2020
Table 51: BGJ398, Clinical Trial Description, 2020
Table 52: Melphalan/HDS, Clinical Trial Description, 2020
Table 53: Derazantinib, Clinical Trial Description, 2020
Table 54: Regorafenib, Clinical Trial Description, 2020
Table 55: Erdafitinib, Clinical Trial Description, 2020
Table 56: Opaganib, Clinical Trial Description, 2020
Table 57: Fimaporfin; Clinical Trial Description, 2020
Table 58: KA2507; Clinical Trial Description, 2020
Table 59: Lenvatinib; Clinical Trial Description, 2020
Table 60 Telotristat ethyl; Clinical Trial Description, 2020
Table 61 DKN-01; Clinical Trial Description, 2020
Table 62: Niraparib Clinical Trial Description, 2020
Table 63: E7090, Clinical Trial Description, 2020
Table 64: A166, Clinical Trial Description, 2020
Table 65: Durvalumab, Clinical Trial Description, 2020
Table: 66 Pembrolizumab, Clinical Trial Description, 2020
Table 67: Futibatinib, Clinical Trial Description, 2020
Table 68: Bintrafusp Alfa, Clinical Trial Description, 2020
Table 69: Entinostat, Clinical Trial Description, 2020
Table 70: Zanidatamab, Clinical Trial Description, 2020
Table 71: Nivolumab, Clinical Trial Description, 2020
Table 72: TAS-102 Clinical Trial Description, 2020
Table 73: Nanoliposomal irinotecan, Clinical Trial Description, 2020
Table 74: T-DXd, Clinical Trial Description, 2020
Table 75: NUC-1031, Clinical Trial Description, 2020
Table 76: Seven Major Market Size of BTC in USD Million (2017–2030)
Table 77: The US Market Size of BTC in USD Million (2017–2030)
Table 78: Market Size by Therapies for Early Stage Disease in the US in USD Million (2017–2030)
Table 79: Market Size of BTC by First Line in the US in USD Million (2017–2030)
Table 80: Market Size of BTC by Second Line in the US in USD Million (2017–2030)
Table 81: Germany Market Size of BTC in USD Million (2017–2030)
Table 82: Market Size by Therapies for Early Stage Disease in Germany in USD Million (2017–2030)
Table 83: Market Size of BTC by First Line in Germany in USD Million (2017–2030)
Table 84: Market Size of BTC by Second Line in Germany in USD Million (2017–2030)
Table 85: France Market Size of BTC in USD Million (2017–2030)
Table 86: Market Size by Therapies for Early Stage Disease in France in USD Million (2017–2030)
Table 87: Market Size of BTC by First Line in France in USD Million (2017–2030)
Table 88: Market Size of BTC by Second Line in France in USD Million (2017–2030)
Table 89: Italy Market Size of BTC in USD Million (2017–2030)
Table 90: Market Size by Therapies for Early Stage Disease in Italy in USD Million (2017–2030)
Table 91: Market Size of BTC by First Line in Italy in USD Million (2017–2030)
Table 92: Market Size of BTC by Second Line in Italy in USD Million (2017–2030)
Table 93: Spain Market Size of BTC in USD Million (2017–2030)
Table 94: Market Size by Therapies for Early Stage Disease in Spain in USD Million (2017–2030)
Table 95: Market Size of BTC by First Line in Spain in USD Million (2017–2030)
Table 96: Market Size of BTC by Second Line in Spain in USD Million (2017–2030)
Table 97: UK Market Size of BTC in USD Million (2017–2030)
Table 98: Market Size by Therapies for Early Stage Disease in UK in USD Million (2017–2030)
Table 99: Market Size of BTC by First Line in UK in USD Million (2017–2030)
Table 100: Market Size of BTC by Second Line in UK in USD Million (2017–2030)
Table 101: Japan Market Size of BTC in USD Million (2017–2030)
Table 102: Market Size by Therapies for Early Stage Disease in Japan in USD Million (2017–2030)
Table 103: Market Size of BTC by First Line in Japan in USD Million (2017–2030)
Table 104:Market Size of BTC by Second Line in Japan in USD Million (2017–2030)
List of Figures
Figure 1: Risk factors and molecular alterations of BTC
Figure 2: Possible Risk Factor and Symptoms
Figure 3: Cells of origin in Cholangiocarcinoma (CCA)
Figure 4: Chronic Inflammation Cycle
Figure 5: Components of the tumor microenvironment in CCA
Figure 6: Factors secreted by cancer-associated fibroblasts
Figure 7: Intracellular pathways involved in CCA proliferation and apoptosis
Figure 8: Common driver genes in HCC and CCA
Figure 9: Molecular genetics of BTC
Figure 10: Algorithm for management and diagnosis of intrahepatic CCA
Figure 11: Algorithm for management and diagnosis of perihilar cholangiocarcinoma
Figure 12: Total Cases of Biliary tract cancers (BTC) in the 7MM (2017–2030)
Figure 13: Total Incident Cases of BTC in the US (2017–2030)
Figure 14: Age-specific Cases of BTC in the US (2017–2030)
Figure 15: Mutation-specific Cases of BTC in the US (2017–2030)
Figure 16: Stage-specific Cases of BTC in the US (2017–2030)
Figure 17: Total Incident Cases of BTC in Germany (2017–2030)
Figure 18: Age-specific Cases of BTC in Germany (2017–2030)
Figure 19: Mutation-specific Cases of BTC in Germany (2017–2030)
Figure 20: Stage-specific Cases of BTC in Germany (2017–2030)
Figure 21: Total Incident Cases of BTC in France (2017–2030)
Figure 22: Age-specific Cases of BTC in France (2017–2030)
Figure 23: Mutation-specific Cases of BTC in France (2017–2030)
Figure 24: Stage-specific Cases of BTC in France (2017–2030)
Figure 25: Total Incident Cases of BTC in Italy (2017–2030)
Figure 26: Age-specific Cases of BTC in Italy (2017–2030)
Figure 27: Mutation-specific Cases of BTC in Italy (2017–2030)
Figure 28: Stage-specific Cases of BTC in Italy (2017–2030)
Figure 29: Total Incident Cases of BTC in Spain (2017–2030)
Figure 30: Age-specific Cases of BTC in Spain (2017–2030)
Figure 31: Mutation-specific Cases of BTC in Spain (2017–2030)
Figure 32: Stage-specific Cases of BTC in Spain (2017–2030)
Figure 33: Total Incident Cases of BTC in UK (2017–2030)
Figure 34: Age-specific Cases of BTC in UK (2017–2030)
Figure 35: Mutation-specific Cases of BTC in UK (2017–2030)
Figure 36: Stage-specific Cases of BTC in UK (2017–2030)
Figure 37: Total Incident Cases of BTC in Japan (2017–2030)
Figure 38: Age-specific Cases of BTC in Japan (2017–2030)
Figure 39: Mutation-specific Cases of BTC in Japan (2017–2030)
Figure 40: Stage-specific Cases of BTC in Japan (2017–2030)
Figure 41: Algorithm for diagnosis and management of Biliary Tract Cancer
Figure 42: A suggested algorithm for the diagnosis and Treatment of cholangiocarcinomas
Figure 43: A suggested treatment algorithm for patients with iCCA
Figure 44: Algorithm for diagnosis and management of dCCA
Figure 45: Flowchart – Management and treatment of patients suspected of perihilar CCA
Figure 46: A suggested diagnosis and treatment algorithm for Gallbladder Cancer
Figure 47: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 48: 7 Major Market Size of BTC in USD Million (2017–2030)
Figure 49: Market Size of BTC in the US, USD Millions (2017–2030)
Figure 50: Market Size by Therapies for Early Stage Disease in the US in USD Million (2017–2030)
Figure 51: Market Size of BTC by First Line in the US in USD Million (2017–2030)
Figure 52: Market Size of BTC by Second Line in the US in USD Million (2017–2030)
Figure 53: Market Size of BTC in Germany, USD Millions (2017–2030)
Figure 54: Market Size for Early Stage Disease in Germany in USD Million (2017–2030)
Figure 55: Market Size of BTC by First Line in Germany in USD Million (2017–2030)
Figure 56: Market Size of BTC by Second Line in Germany in USD Million (2017–2030)
Figure 57: Market Size of BTC in France, USD Millions (2017–2030)
Figure 58: Market Size by Therapies for Early Stage Disease in France in USD Million (2017–2030)
Figure 59: Market Size of BTC by First Line in France in USD Million (2017–2030)
Figure 60: Market Size of BTC by Second Line in France in USD Million (2017–2030)
Figure 61: Market Size of BTC in Italy, USD Millions (2017–2030)
Figure 62: Market Size by Therapies for Early Stage Disease in Italy in USD Million (2017–2030)
Figure 63: Market Size of BTC by First Line in Italy in USD Million (2017–2030)
Figure 64: Market Size of BTC by Second Line in Italy in USD Million (2017–2030)
Figure 65: Market Size of BTC in Spain, USD Millions (2017–2030)
Figure 66: Market Size by Therapies for Early Stage Disease in Spain in USD Million (2017–2030)
Figure 67: Market Size of BTC by First Line in Spain in USD Million (2017–2030)
Figure 68: Market Size of BTC by Second Line in Spain in USD Million (2017–2030)
Figure 69: Market Size of BTC in UK, USD Millions (2017–2030)
Figure 70: Market Size by Therapies for Early Stage Disease in UK in USD Million (2017–2030)
Figure 71: Market Size of BTC by First Line in UK in USD Million (2017–2030)
Figure 72: Market Size of BTC by Second Line in UK in USD Million (2017–2030)
Figure 73: Market Size of BTC in Japan, USD Millions (2017–2030)
Figure 74: Market Size by Therapies for Early Stage Disease in Japan in USD Million (2017–2030)
Figure 75: Market Size of BTC by First Line in Japan in USD Million (2017–2030)
Figure 76: Market Size of BTC by Second Line in Japan in USD Million (2017–2030)
Figure 77: Market Drivers
Figure 78:Market Barriers
Figure 79: SWOT Analysis of Biliary Tract Cancer
Incyte Corporation
Loxo Oncology/Bayer
Roche
Agios Pharmaceuticals
QED Therapeutics
Delcath Systems
Basilea PharmaceuticaL
Bayer
Janssen Pharmaceutical
RedHill Biopharma
PCI biotech
Karus Therapeutics
Eisai
Lexicon Pharmaceuticals/TerSera Therapeutics
Leap Therapeutics
GlaxoSmithKline
Eisai
KLUS Pharma
AstraZeneca
Merck Sharp & Dohme Corp.
Taiho Oncology
Celgene
Hutchison Medipharma Limited
Merck Sharp & Dohme Corp.
Syndax Pharmaceuticals
BeiGene
Bristol-Myers Squibb
Taiho Pharma
Ipsen
Daiichi Sankyo
NuCana
